Skip to content

Use of eranda bhrusta haritaki in the management of painful menstruation (udavartani yonivayapada)

Clinical evaluation of the role of eranda bhrusta haritaki in the management of Uudavartani yonivayapada.

Status
Active, not recruiting
Phases
Phase 3
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2023/05/052281
Enrollment
40
Registered
2023-05-03
Start date
Unknown
Completion date
Unknown
Last updated
2024-01-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: N738- Other specified female pelvic inflammatory diseases

Interventions

None listed

Sponsors

Dr Neha Yadav
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Age between 15 years to 45 years Patient diagnosis with Udavartini Yonivayapada

Exclusion criteria

Exclusion criteria: Patient having Any Malignancy or Missed Period Patient have diagnosed with HIV STD HCV Patient having a pregnancy in midterm Patient having any pelvic palpable pathology

Design outcomes

Primary

MeasureTime frame
Improvement in pain and discomfort in perimenstrual periodTimepoint: 12week The trial drug will be given for 3months with anupana and follow up after cessation of medicine

Secondary

MeasureTime frame
State of constipation and also in apanavata gat vayadhiTimepoint: After analyzing all parameter the result will be assessed on the basis of symptomatic relief and improvement Partially improvement after 4 week-patient get 40 -60 percent relief sing and symptoms Improvement after 8 week -patient get 60-80 percent relief form sing and symptoms Cured after 12 week - patient get 80 -100 percent relief form sing and symptoms

Countries

India

Contacts

Public ContactDr Rama khatavkar

Vaidya Yagya Dutt Sharma Ayurveda Mahavidhalya khurja Bulandshahr Uttar Pradesh

rama.khatavkar212@gmail.com87555696992

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026